Correction to: DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells.
作者信息
Li Weijing, Liu Shuguang, Wang Chanjuan, Cui Lei, Zhao Xiaoxi, Liu Wei, Zhang Ruidong, Li Zhigang
机构信息
Laboratory of Hematologic Diseases, Beijing Children's Hospital, Beijing Pediatric Research Institute, Capital Medical University, National Center for Children's Health, Beijing, China.
Beijing Key Laboratory of Pediatric Hematology-Oncology, Beijing, China.
出版信息
BMC Cancer. 2023 Apr 21;23(1):366. doi: 10.1186/s12885-023-10862-x.
Abstract
摘要
相似文献
1
Correction to: DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells.对《DNMT3A低表达与儿童B-急性淋巴细胞白血病预后不良相关并赋予白血病细胞对柔红霉素的抗性》一文的更正
BMC Cancer. 2023 Apr 21;23(1):366. doi: 10.1186/s12885-023-10862-x.
2
DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells.DNMT3A 低表达与儿童 B-ALL 的不良预后相关，并使白血病细胞对柔红霉素产生耐药性。
BMC Cancer. 2023 Mar 18;23(1):255. doi: 10.1186/s12885-023-10724-6.
3
Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.儿童急性淋巴细胞白血病细胞内柔红霉素浓度、主要穹窿蛋白/肺耐药蛋白表达与蒽环类药物耐药性之间的关系
Leukemia. 1999 Dec;13(12):2023-30. doi: 10.1038/sj.leu.2401576.
4
DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.DNMT3A R882H 突变通过调节 NRF2/NQO1 通路驱动急性髓系白血病对柔红霉素耐药。
Cell Commun Signal. 2022 Oct 27;20(1):168. doi: 10.1186/s12964-022-00978-1.
5
DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.DNMT3A R882H 突变通过 NRF2/NQO1 轴调节糖酵解促进急性白血病细胞存活。
Cell Signal. 2023 May;105:110626. doi: 10.1016/j.cellsig.2023.110626. Epub 2023 Feb 7.
6
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.与柔红霉素相比，携带DNMT3A外显子23突变的急性髓系白血病患者从去甲氧柔红霉素治疗中是否获益？一项单中心经验。
Oncotarget. 2011 Nov;2(11):850-61. doi: 10.18632/oncotarget.347.
7
The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.PSC 833、环孢素A、维拉帕米和金雀异黄素对儿童急性淋巴细胞白血病柔红霉素体外细胞毒性及细胞内含量的调节作用。
Leukemia. 1998 Jun;12(6):912-20. doi: 10.1038/sj.leu.2401035.
8
Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression.bcr-abl阳性急性淋巴细胞白血病对柔红霉素的耐药性并非由mdr1基因表达介导。
Am J Hematol. 2002 Nov;71(3):172-6. doi: 10.1002/ajh.10212.
9
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.DNMT3A突变通过受损的核小体重塑促进急性髓性白血病对蒽环类药物的耐药性。
Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.
10
Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
Eur J Haematol. 1992 May;48(5):254-8. doi: 10.1111/j.1600-0609.1992.tb01803.x.
本文引用的文献
1
DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells.DNMT3A 低表达与儿童 B-ALL 的不良预后相关，并使白血病细胞对柔红霉素产生耐药性。
BMC Cancer. 2023 Mar 18;23(1):255. doi: 10.1186/s12885-023-10724-6.
Zotero 插件